The CLIP²-ILIAD (Imaging and Longitudinal Investigations to Ameliorate Decision-making) has been awarded the prestigious certification for the fourth time!
This project, led by the GCS IRéCAN (Institut de Cancérologie de l’Ouest, CHU Nantes, and CHU Angers), has earned a dual certification: adult and pediatric. Only sixteen centers in France have received this label, positioning them as key players in therapeutic innovation.
The CLIP² centres, initiated by the Institut National du Cancer (INCa) in 2010, aim to facilitate early-phase clinical trials. These early-phase trials are designed to evaluate a new treatment in humans after it has passed various laboratory tests. This initial step is followed by later phases, potentially leading to the commercialization of the drug a few years later.
For more information, see the CLIP²-ILIAD press release.
To find details about the trials conducted by CLIP²-certified centres, visit DATAVIZ SCREEN.
